Malondialdehyde Mediated Alpha-Synuclein Aggregation: A Plausible Etiology of Parkinson's Disease in Oxidative Stress

Harsh Thakkar1, Sayan Chatterjee2, Arvind Verma1

  • 1Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Opposite Air force Station Palaj, Gandhinagar, Gujarat 382355, India.

PubMed

Insights

Malondialdehyde (MDA) modifies alpha-synuclein (α-Syn), promoting protein aggregation and motor deficits relevant to Parkinson's disease (PD). This study reveals MDA-induced α-Syn changes contribute to neurodegeneration in a PD mouse model.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Malondialdehyde (MDA), a lipid peroxidation byproduct, alters protein structure and function in disease.
  • Alpha-synuclein (α-Syn) aggregation is central to Parkinson's disease (PD) pathogenesis.
  • MDA's role in modifying α-Syn and its impact on PD are not fully understood.

Purpose of the Study:

  • To investigate if MDA induces structural alterations in α-Syn, promoting aggregation and toxicity.
  • To explore the potential contribution of MDA-modified α-Syn to Parkinson's disease mechanisms.

Main Methods:

  • In vivo studies involving intracerebral injection of MDA and MDA-modified α-Syn in mice.
  • Behavioral assessments for motor function, immunohistochemistry for α-Syn aggregation.
  • Development of an extraction protocol and nLC-HRMS/MS with 15N-labeled α-Syn for absolute quantification.

Main Results:

  • MDA-induced modifications significantly alter α-Syn structure and enhance its aggregation.
  • The mouse model exhibited non-reversible motor function decline, neurodegeneration, and protein aggregation.
  • Quantification methods successfully measured MDA-modified α-Syn in brain tissue.

Conclusions:

  • MDA-modified α-Syn aggregation contributes to neurodegenerative processes mimicking PD.
  • This study elucidates a molecular mechanism linking lipid peroxidation byproducts to PD etiology.
  • Findings highlight the critical role of MDA-modified proteins in Parkinson's disease pathogenesis.